Last reviewed · How we verify
keto-analogs
keto-analogs is a Ketone body analog Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 3 development for Type 2 diabetes treatment.
Keto-analogs are synthetic compounds that mimic the effects of ketone bodies, which are produced by the liver when it breaks down fat for energy.
Keto-analogs are being studied as a potential intervention for various conditions, including kidney disease, renal failure, type 2 diabetes mellitus, and malnutrition, according to ClinicalTrials.gov. Keto-analogs are a type of protein modality, as indicated by ChEMBL, suggesting they may work by interacting with proteins in the body.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | keto-analogs |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Ketone body analog |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Keto-analogs work by increasing the levels of ketone bodies in the blood, which can help to reduce the need for glucose and improve insulin sensitivity. This can be beneficial for people with type 2 diabetes or those who are at risk of developing it. Additionally, keto-analogs may have anti-inflammatory and anti-cancer properties.
Approved indications
- Type 2 diabetes treatment
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION) (PHASE3)
- Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients (PHASE4)
- Impact of Low Protein Diet Supplemented With Ketoanalogues Supplementation on Uremic Toxins Production (PHASE3)
- Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- keto-analogs CI brief — competitive landscape report
- keto-analogs updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about keto-analogs
What is keto-analogs?
How does keto-analogs work?
What is keto-analogs used for?
Who makes keto-analogs?
What drug class is keto-analogs in?
What development phase is keto-analogs in?
What are the side effects of keto-analogs?
Related
- Drug class: All Ketone body analog drugs
- Manufacturer: Hospices Civils de Lyon — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing